It is a new weapon in the fight against Covid-19. Since the beginning of October, French people vulnerable to the virus can receive a new dose of vaccine, with a modified product, called “bivalent”, specifically targeting Omicron and its sub-variants. Both Pfizer and Moderna have developed one using messenger RNA technology. According to the first laboratory, this would be more effective than the original vaccine.
According to results published this week, Pfizer’s bivalent vaccine, injected as a booster dose, would generate antibody levels four times higher than the vaccine developed in the first months of the pandemic, assures the American company. To reach this conclusion, the scientists compared blood samples between people vaccinated with the bivalent, and those vaccinated with the initial product. However, only about forty samples appeared in each group.
